Holen Sie sich die Stockscreener-App
133.25
3.77%
4.84
Schlusskurs vom Vortag:
$128.41
Offen:
$129
24-Stunden-Volumen:
1.73M
Relative Volume:
1.54
Marktkapitalisierung:
$13.40B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$478.60M
KGV:
28.55
EPS:
4.6676
Netto-Cashflow:
$748.70M
1W Leistung:
+3.38%
1M Leistung:
+1.94%
6M Leistung:
-4.88%
1J Leistung:
+31.44%
1-Tages-Spanne:
$128.41
$133.74
1-Wochen-Bereich:
$125.64
$133.74
52-Wochen-Spanne:
$98.95
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
133.25 | 13.40B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Persistence Data And Options Activity - simplywall.st
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Gain -- G - GuruFocus
Neurocrine's Acquisition Impacts Soleno Therapeutics (SLNO) Rati - GuruFocus
How New Real-World INGREZZA Data Versus AUSTEDO XR Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Hold at Zacks Research - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Massachusetts Financial Services Co. MA Sells 10,415 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Q3 2025 Earnings Preview - MSN
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup - ChartMill
Neurocrine Expands CNS Pipeline With Nxera Schizophrenia Trial And Milestones - Sahm
How Investors May Respond To Neurocrine Biosciences (NBIX) INGREZZA Real-World Persistence Edge Over AUSTEDO XR - Yahoo Finance
Is It Time To Reassess Neurocrine Biosciences (NBIX) After Its Recent Share Price Pullback? - Yahoo Finance
Real World INGREZZA Data May Support Neurocrine’s Tardive Dyskinesia Lead - Sahm
Neurocrine Biosciences (NBIX) Stock Price, News & Analysis - MarketBeat
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine Biosciences | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A NEUROCRINE BIOSCIENCES - StreetInsider
Neurocrine Biosciences (NBIX) seeks approval for 4M-share equity plan boost - Stock Titan
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock? - Zacks Investment Research
Neurocrine Biosciences identifies new CRF2 receptor agonists - BioWorld News
Robeco Institutional Asset Management B.V. Purchases 85,076 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking - MSN
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100 - GuruFocus
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Underv - GuruFocus
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results - The AI Journal
Valbenazine Demonstrates Higher Persistence vs Deutetrabenazine in TD Patients - HMP Global Learning Network
INGREZZA shows higher treatment persistence than AUSTEDO XR in study - StreetInsider
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR - ChartMill
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Burney Co. Cuts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
FDA’s FIH plans. Plus: billion-dollar deals, funds — a BioCentury podcast - BioCentury
Investment Recap: Does Neurocrine Biosciences Inc have pricing power2026 Volume Leaders & Weekly High Return Stock Forecasts - baoquankhu1.vn
Technical Analysis: Can Neurocrine Biosciences Inc maintain its current growth rate2026 Dividend Review & Low Volatility Stock Suggestions - baoquankhu1.vn
Neurocrine Acquires Soleno for $2.9B - San Diego Business Journal
Portfolio Shifts: Is Neurocrine Biosciences Inc forming a double bottom2026 Momentum Check & Fast Gaining Stock Reports - baoquankhu1.vn
Nxera Pharma earns $22.5 million milestone haul from Neurocrine - Business Weekly
Nxera Pharma Co., Ltd. Initiates and Doses First Patient in Phase 2 Trial of Nbi-1117570 for Adults with Schizophrenia - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia - manilatimes.net
Nxera Pharma’s Partner Neurocrine Biosciences Doses First - GlobeNewswire
The week in pharma: action, reaction and insight – week to April 10, 2026 - The Pharma Letter
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
(NBIX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
Volume Recap: Is Neurocrine Biosciences Inc forming a breakout patternEarnings Trend Report & Real-Time Market Trend Scan - baoquankhu1.vn
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN
Some May Be Optimistic About Neurocrine Biosciences' (NASDAQ:NBIX) Earnings - 富途牛牛
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.22%
2.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):